Indivior PLC 8-K filings

Indivior and Supernus Pharmaceuticals announced a merger of equals to create a diversified CNS biopharmaceutical leader with significant scale and an expanded portfolio of 11 medicines.

Indivior Pharmaceuticals announced robust second-quarter 2026 financial results, exceeding expectations with significant year-over-year growth in revenue and profitability, leading to an upward revision of its full-year financial outlook.

Indivior Pharmaceuticals and Supernus Pharmaceuticals announced a definitive agreement to merge, creating a diversified CNS biopharmaceutical company with combined annual revenues of approximately $2.2 billion.

Indivior Pharmaceuticals reports the elimination of its Chief Scientific Officer role and confirms the successful re-election of its board and auditor ratification.

Indivior Pharmaceuticals, Inc. has entered into an accelerated share repurchase agreement to buy back $175 million of its common stock.

Indivior Pharmaceuticals announced robust first-quarter 2026 financial results, driven by significant SUBLOCADE revenue growth, and consequently raised its full-year 2026 financial guidance.

Indivior Pharmaceuticals, Inc. has issued $550 million in 0.625% Convertible Senior Notes due 2031, enhancing financial flexibility and refinancing existing debt.

Indivior Pharmaceuticals announced a proposed private offering of $400 million in convertible senior notes due 2031, aiming to refinance debt and repurchase shares.

Indivior Pharmaceuticals, Inc. announced record SUBLOCADE revenue and adjusted EBITDA for Q4 and full-year 2025, alongside a new $400 million share repurchase program and reaffirmed 2026 guidance.

Indivior Pharmaceuticals, Inc. has successfully completed its redomiciliation from the United Kingdom to the United States, with its common stock continuing to trade on Nasdaq under the symbol INDV.

Indivior PLC announced its full-year 2026 financial guidance, projecting accelerated SUBLOCADE revenue growth and significant adjusted EBITDA expansion driven by a simplified operating model.

Indivior PLC announced its inclusion in the S&P SmallCap 600 index, effective December 22, 2025, aligning its capital markets presence with its U.S. business profile.

Indivior PLC announced base salary increases for its Chief Executive Officer and Chief Financial Officer, effective January 1, 2026.

Indivior PLC shareholders overwhelmingly approved a scheme of arrangement and related amendments to the company's articles of association, paving the way for its re-domiciliation.

Indivior PLC announced the full payment of its $295 million outstanding obligation to the U.S. Department of Justice, terminating a significant resolution agreement.

Indivior PLC plans to re-domicile from the U.K. to Delaware, establishing Indivior Pharmaceuticals, Inc. as its new U.S. holding company to maximize U.S. listing benefits.

Indivior PLC amends its 8-K filing, detailing an enterprise-wide 'Indivior Action Agenda' to optimize its global business, exit non-core markets, and target $150 million in annual operating expense savings.

Indivior PLC reported strong Q3 2025 financial results, driven by SUBLOCADE growth and strategic business optimization, leading to raised full-year 2025 financial guidance.

Indivior PLC announced its intent to redomicile its parent company from the U.K. to Delaware, establishing a new U.S. parent, Indivior Pharmaceuticals, Inc.

Indivior PLC announced an enterprise-wide restructuring initiative, the 'Indivior Action Agenda,' involving headcount reductions and real estate consolidations, expected to incur $39 million to $50 million in pre-tax charges.

Indivior PLC announced new employment and non-competition agreements for CFO Ryan Preblick, aligning his terms with current U.S. executive standards without changing his compensation or responsibilities.

Indivior PLC announced the appointment of non-executive director Stuart A. (Tony) Kingsley to its Audit & Risk and Compensation Committees, effective July 1, 2025.

Indivior PLC reported robust second-quarter 2025 financial results, driven by strong SUBLOCADE revenue and U.S. SUBOXONE Film pricing stability, leading to a significant increase in its full-year financial guidance.

Indivior PLC announced its inclusion in the U.S. small-cap Russell 2000 and broad-market Russell 3000 indexes, effective June 30, 2025, enhancing its capital markets presence.

Indivior PLC announced the appointment of biopharmaceutical executive Tony Kingsley to its Board of Directors and detailed new equity arrangements designed to increase share ownership among its non-executive directors.

Indivior PLC has reaffirmed its 2025 financial guidance, projecting total net revenue between $955 million and $1.025 billion, as it transitions its primary listing to Nasdaq and focuses on its U.S. commercial portfolio and opioid use disorder pipeline.

Indivior PLC announced its intention to cancel its secondary listing on the London Stock Exchange, effective July 25, 2025, to consolidate its primary listing on Nasdaq, citing U.S. revenue focus and higher Nasdaq liquidity.

Indivior PLC has amended the vote tally for the election of Dr. David Wheadon at its 2025 Annual General Meeting (AGM), with all other details remaining unchanged.

Indivior PLC held its 2025 Annual General Meeting on May 8, 2025, with all resolutions duly passed by shareholders.

Indivior PLC reports first quarter 2025 results, with total net revenue of $266 million and reaffirms its FY 2025 guidance.